Business Wire

PQE Group and Techniconsult Group: a Strategic Alliance to Provide Strategic Consulting in the Life Science Industry

Share

PQE Group, a multinational consulting corporation operating on the side of Pharmaceutical and Medical Device Quality, and Techniconsult Group, an engineering company, are both leaders in the Life Science industry and have signed a cross-holding agreement, strengthening their presence on the national and international market. The partnership brings together two matchless companies holding the market’s high spot.

Both companies are Italian excellences from Tuscany and family-run businesses with numerous points in common. Their goal is to make their skills and expertise available to clients and the Pharmaceutical industry for successful engineering integrated projects, becoming a point of attraction for worldwide talents and companies. The Companies also pay particular attention to the values they share, with an emphasis on CSR activities and the well-being of their workforce, which counts 2000 people worldwide, of which 1000 are in Italy.

Techniconsult Group, founded in Florence in 1987, is becoming a benefit company, with a turnover of 27 million euros (+36% compared to 2021). The company has been supporting its clients for over 30 years in the design, management, and building of pharmaceutical facilities, studying and applying efficient and smart engineering solutions through a flexible approach.

Techniconsult’s model integrates perfectly with the know -how developed by PQE, a giant consulting company for the Pharma industry, with a turnover prediction for 2022 of more than 90 millions euro (+68% compared to 2021). Thanks to its international reach and reputation, it has brought the Made in Italy brand to the world. The financial maneuver that the companies have agreed on consists of shares exchanges that will deeply integrate the two companies with the goal of growing together.

This operation is part of the PQE Federation path, a concept internally developed by PQE Group founder Gilda D’Incerti, which aims to create a global network with vertical specializations in the Pharma industry that are able to offer its clients integrated and complementary solutions. The same reasoning has been adopted by Techniconsult Group owners Rosario Lo Presti and Pier Angelo Galligani, who, in the last years, have signed various agreements in Italy and other countries to secure the position of their company as a first-class vendor in the Pharmaceutical field.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Laura Piccioli – PQE Group – pressoffice@pqegroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BGO Announces US$5.1 Billion Capital Raise for Its Asia Value-Add Real Estate Strategy, Marking Largest Closed-End Fundraise in Firm’s History5.6.2025 23:00:00 EEST | Press release

BGO today announced the final close of BentallGreenOak Asia IV (“BGO Asia Fund IV” or the “Fund”), its flagship Asia-focused value-add real estate strategy, raising over US$5.1 billion in total capital commitments for the Fund and co-investment sidecars. The Fund represents the largest closed-end capital raise in BGO’s history, underscoring the firm’s history and reputation as a premier global real estate investment manager in Asian markets. BGO Asia Fund IV targets value-add opportunities in office, hospitality, and logistics assets across Japan, South Korea, Australia, and Singapore. Japan represents a central pillar of our investment strategy, driven by regulatory reforms and corporate governance shifts that are catalyzing an estimated US$3 trillion in non-core asset divestitures. “Japan is undergoing a profound transformation, and we see strong, sustained tailwinds across the region,” said Fred Schmidt, Managing Partner and Chairman of Asia, BGO. “Tokyo is one of the world’s larges

PIF and FIFA forge partnership for FIFA Club World Cup 2025™5.6.2025 20:00:00 EEST | Press release

PIF and FIFA today announced PIF as an official partner of FIFA Club World Cup 2025™, which will take place in the U.S. from June 14 to July 13, 2025. The partnership reflects FIFA and PIF’s shared vision to enable greater participation in sports by unlocking new opportunities, fostering innovation and engaging fans around the world. With a focus on youth, the partnership will provide opportunities for young people, supporting FIFA in its efforts to engage and inspire at a grassroots level. The new FIFA Club World Cup 2025™ marks a fresh chapter for club football on the global stage. It will feature 32 of the world’s top football clubs, bringing together champions from all six FIFA confederations for a month-long tournament in 11 cities across the U.S. Romy Gai, Chief Business Officer at FIFA, said:“We are delighted to welcome PIF as a partner of the FIFA Club World Cup 2025™. Together, we look forward to delivering a historic tournament that inspires and unites fans from around the wo

Orange Logic Appoints Ben Colenso as Managing Director, EMEA5.6.2025 19:41:00 EEST | Press release

Orange Logic, the leader in digital asset management and content orchestration, today announced the appointment of Ben Colenso as Managing Director for EMEA. Based in the UK, Colenso will spearhead Orange Logic’s regional strategy, customer enablement, and market expansion efforts, as the company accelerates its global footprint. Colenso brings 20 years of experience in technology and media production, having most recently led the technology strategy for Hogarth, WPP’s content experience company. Known for solving complex problems for some of the world’s most iconic brands with his customer-centric approach, Colenso will play a critical role in strengthening Orange Logic’s presence and partnerships across EMEA which span customers such as ITV, Pearson, GSK, Ubisoft and Tourism Ireland amongst others. “Ben’s appointment reflects our deep commitment to EMEA, where we continue to see strong momentum and increasing demand from some of the world’s most sophisticated enterprises,” said Brian

Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 20405.6.2025 18:22:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it has extended full support coverage for all SAP ECC 6.0 and S/4HANA releases through 2040, without any need to complete a migration to S/4HANA on RISE as required by SAP for clients who want to remain on SAP’s Annual Support and receive full support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605581964/en/ Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 2040 Rimini Street SAP Clients Gain Long-Term Savings to Self-Fund Innovation Current Rimini Support™ for SAP clients are not impacted by SAP’s end-of-maintenance dates. With unmatched support, service and guidance from Rimini Street as a single, trusted partner – clients can keep systems r

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform5.6.2025 17:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice® fully human antibody platform family. It underscores the continued advancement of Biocytogen’s comprehensive global patent strategy and highlights the innovation and international recognition of the company’s proprietary technologies. RenMab™ mice are a core member of Biocytogen’s independently developed RenMice® fully human antibody discovery platform family. Using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye